Key Highlights

● Larimar Therapeutics appointed John B. Harlow, Jr., 51, as President and Chief Operating Officer, effective September 29, 2026.

● Mr. Harlow served as Chief Commercial Officer of Esperion Therapeutics from November 2025 to September 2026, the filing says.

● His pay includes a $560,000 base salary, a $35,000 sign-on bonus, an 800,000-share stock option and 50,000 restricted stock units.

● Severance is nine months of base pay, or 12 months if termination follows a change in control within one year.

Larimar Therapeutics, Inc. (NASDAQ:LRMR) reported in a Form 8-K filed on September 29, 2026 that its board appointed John B. Harlow, Jr. as President and Chief Operating Officer, effective September 29, 2026. Mr. Harlow is 51 and most recently served as Chief Commercial Officer of Esperion Therapeutics (NASDAQ:ESPR). The filing lays out his employment terms, including a $560,000 base salary, a stock option covering 800,000 shares and a grant of 50,000 restricted stock units.

The Appointment and Mr. Harlow's Background

The 8-K reports the appointment under Item 5.02, which covers officer appointments and related compensation arrangements. It says Mr. Harlow's appointment as President and Chief Operating Officer is effective on the filing date. The filing does not identify a predecessor in the role. It states that Mr. Harlow has no family relationship with any of the company's executive officers or directors and that there was no arrangement under which he was appointed. Chief Executive Officer Carole S. Ben-Maimon, M.D., signed the report.

According to the filing, Mr. Harlow was Chief Commercial Officer of Esperion Therapeutics from November 2025 to September 2026. Before that he held the same title at Melinta Therapeutics from March 2021 to November 2025, and at Baudax Bio from November 2019 to March 2021. From October 2016 to November 2019 he held Executive Vice President and Vice President commercial roles at Recro Pharma. His earlier career included positions at Endo, Shionogi, Pfizer (NYSE:PFE) and Novartis (NYSE:NVS), and he was an equity research analyst at Merrill Lynch. He holds a Bachelor of Science in Biology from Lehigh University and an MBA in Pharmaceutical Management from Seton Hall University.

Compensation and Severance

Under his employment agreement, Mr. Harlow receives an annual base salary of $560,000 and a $35,000 sign-on bonus. His annual bonus target is 40 percent of base salary, prorated for 2026. He receives a stock option to buy 800,000 shares, with an exercise price equal to the closing price on the effective date. The option vests 25 percent after one year and the remaining 75 percent in 36 equal monthly installments. He also receives 50,000 restricted stock units, which vest in four equal annual installments beginning at the first anniversary.

The filing describes two severance scenarios. If Mr. Harlow is terminated without cause or resigns for good reason, he is eligible for nine months of base salary, his prior-year bonus and nine months of COBRA premiums. If such a termination occurs within one year after a change in control, he is eligible for 12 months of base salary plus target bonus, his prior-year bonus and 12 months of COBRA premiums. The filing notes that the terms are described in the employment agreement itself and does not refer to a separate offer letter.

What the Filing Does Not Say

The 8-K does not identify who previously held the role, and the submission contains no press release. It is a compensation-focused personnel notice and does not provide financial results or an update on the company's programs. The company states that it will file the full text of the employment agreement with its quarterly report on Form 10-Q for the third quarter of 2026, so the complete terms, including any definitions of cause and good reason, will be available only when that report is filed.

Harlow Agreement Headed to Larimar's Q3 10-Q

The main scheduled item is the company's Form 10-Q for the third quarter of 2026, which is expected to include the employment agreement as an exhibit. The first vesting dates for the option and the restricted stock units fall one year after the effective date.